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Abstract: Imidazoles fused with a cyclic system in 1,5-position
were synthesized via the van Leusen imidazole synthesis em-
ploying saturated aliphatic tricycles including an imine function
in the base catalyzed cycloaddition reaction with p-toluene-
sulfonyl-methyl isocyanide (TosMIC). Thereby, N-(tosyl-
methyl)formamide, a decomposition product of TosMIC, was
found to act as a promoter of this reaction leading to considera-
bly reduced reaction times and improved yields. Mechanistic
studies revealed that N-(tosylmethyl)formamide is transformed
Introduction
Imidazole rings are a common structural motif present in many
natural products, medicinal drugs, and chemical compounds.[1]
Thus, imidazole rings are found for example in numerous anti-
cancer, antibacterial, antiparasitic, antihistaminic, antihyperten-
sive, antineuropathic, and antifungal drugs.[2] Crop protection
agents containing an imidazole heterocycle, for instance Pro-
chloraz (1) or Imazalil (2) (Figure 1), are widely applied to main-
tain crop quality and quantity.[1a,3]
Since the first imidazole syntheses by Debus and Radziszew-
ski in the 19th century, a multitude of synthetic methods for the
preparation of imidazoles has evolved.[4] A common approach
for the preparation of imidazoles is the van Leusen imidazole
synthesis which is based on the 1,3-cycloaddition of tosyl-
methyl isocyanide (TosMIC) with imines under basic condi-
tions.[4c,5] By this method, a large variety of either 1,5-di-, or
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into N-methyleneformamide acting as a catalyst in this reaction
under the applied basic conditions. Being a Michael acceptor,
the employed imines add to this compound, thus being trans-
formed into iminium ions. The so formed intermediates facili-
tate the first step of the van Leusen imidazole synthesis, which
is the addition of deprotonated TosMIC to the iminium subunit.
N-methyleneformamide is finally reformed during the overall
reaction and can thus be considered as an organocatalyst of
the studied cycloaddition reaction.
Figure 1. Structures of Prochloraz (1), Imazalil (2) and Fadrozole (3).
1,4,5-tri-substituted imidazoles employing acyclic imines as
starting materials has been synthesized.[5,6] In contrast, exam-
ples in which the van Leusen imidazole synthesis has been ap-
plied to the construction of imidazoles displaying a fused ring
system originating from 1,5-position are less common which is
likely due to the fact that cyclic imines are less abundant than
their acyclic counterparts.
Exhibiting an imine subunit, pyrazine-2(1H)one derivatives
have been employed in cycloaddition reactions with TosMIC
yielding the corresponding ring fused systems that served as
intermediates for the development of anticancer agents.[7] Fur-
ther examples for the construction of 1,5-ring-fused imidazoles
by means of TosMIC are found in syntheses of imidazobenzodi-
azepine and imidazo -carboline derivatives.[8–10] Furthermore,
also nitrogen containing heteroaromatic compounds like
quinolone, isoquinoline, and quinoxaline formally displaying a
C=N subunit have successfully been employed in the synthesis
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Figure 2. Structures of 1,5-ring-fused imidazoles synthesized from TosMIC and
pyrazine-2(1H)ones (4);[7] benzodiazepines (5);[9] -carboline derivatives (6)[10]
and nitrogen containing heteroaromatics (7).[11]
Though, N-fused imidazoles with a saturated aliphatic cycle
in 1,5-position are of great interest as for example Fadrozole (3),
a non-steroidal aromatase inhibitor used for the treatment of
breast cancer,[12] cycloaddition reactions of basic cyclic imines
devoid of any additional functionalities have not been explored
in the van Leusen imidazole synthesis, except for a cycloaddi-
tion reaction with 4-azahomoadamant-4-ene.[13]
It is likely to be attributed to the limited availability of appro-
priate cyclic imines which are devoid of any additional unsatu-
ration that cycloaddition reactions of this type of compounds
with TosMIC for the preparation of the respective N-fused imid-
azoles have hardly been explored so far. We have repeatedly
reported on the synthesis of this kind of alicyclic imines by acid
catalyzed intramolecular cycloaddition reactions of 4,4-disubsti-
tuted 1,4-dihydropyridines (1,4-DHPs) with one of the 4-substit-
uents serving as dienophile.[14] The tricyclic imines resulting
from these reactions exhibiting a highly defined geometry are
to be considered as valuable building blocks for the construc-
tion of drug like compounds, as they represent scaffolds of high
Table 1. Synthesis of symmetric tricyclic imines 13a–f.
[a] The yield of 11 and 12 in the crude product and the product ratio were determined using 1H NMR spectroscopy with 2,4,6-collidine as internal standard.
Isol. yields surpassing the NMR-yield are within error deviations.[16] [b] Not determinable due to low signal intensity. [c] Not determined.
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rigidity encompassing well defined trajectories for individual
substituents. To further improve the versatility of these building
blocks, we now intended to utilize the imine function for the
anellation of an imidazole ring by the van Leusen imidazole
synthesis to introduce a polar subdomain in this otherwise
apolar compounds.
Results and Discussion
As starting material for the anellation of an imidazole ring, we
intended to use tricyclic imines which are symmetric, possess
substituents R at bridge heads of different size (CH3, C6H5), and
vary with regard of the length of the “upper bridge” (n = 0–2).
Therefore, compounds 13a–13f should be employed for this
purpose. For the synthesis of these compounds, 13a–13f, the
synthetic procedure developed for the construction of related,
but non-symmetrically substituted tricyclic imines should be
followed.[14a] Accordingly, in the first step appropriately 4,4-
disubstituted 1,4-dihydropyridines should be prepared via reac-
tion of N-silylpyridinium ions with bisorganomagnesium com-
pounds. An acid catalyzed intramolecular hetero-Diels-Alder-
reaction of these 4,4-disubstituted 1,4-dihydropyridines – with
one 4-substituent exhibiting a double bond serving as dieno-
phile – should finally furnish the respective tricyclic imines.
Hence, for the synthesis of the required 1,4-DHPs 11a–11f,
following a published procedure, 4-methylpyridine 8a or
4-phenylpyridine 8b were treated with TIPSOTf (1.1 equiv., in
CH2Cl2 at 20 °C for 15 min) to generate the corresponding
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the respective bisorganomagnesium species 10a–10f (–30 °C).
However, for economic reasons here only 0.55 equivalents in-
stead of 1.1 equiv. of the organometallic reagents were used in
contrast to the literature procedure.[14a] As in related cases,[14,15]
these reactions resulted in mixtures of the regioisomeric
1,2- and 1,4-addition products, i.e. of 11a–11f and 12a–12f. In
these mixtures according to 1H NMR quantification based on
the use of an internal standard, the desired 1,4-addition prod-
ucts 11a–11e clearly prevailed in each case over the respective
1,2-addition products 12a–12e. Thus, the 1H NMR yields for
11a–11e amounted to 26–66 % whereas for 12a–12e, they
ranged from values partly too low for an accurate determina-
tion (<1 %) to up to 20 %. In line with these results, 11a–11e
could finally be isolated in yields from 19–55 %. Dihydropyr-
idine 11f, for which the crude product had not been analyzed
by 1H NMR, was isolated in a yield of 55 %, indicating that also
this addition reaction had proceeded in favor of the 1,4-addi-
tion product.
The successive intramolecular hetero-Diels-Alder reaction of
11a–11f could finally be accomplished by subjecting the ob-
tained 4,4-disubstituted 1,4-dihydropyridines 11a–11f to TFA
(15 equiv.) in pentane (at 20 °C for 15 min), i.e. reaction condi-
tions published for related cycloaddition reactions before.[14a]
That way the desired tricyclic imines 13a–13f were obtained in
good to excellent yields (Table 1, entries 1–6: 62–95 %).
Next, we focused on the anellation of an imidazole ring to
the imine function of the synthesized tricyclic imines 13a–13f
to generate the desired condensation products, imidazole de-
rivatives 14. This we intended to perform as already mentioned
afore according to the so called van Leusen imidazole synthesis,
in which imines are reacted with TosMIC in the presence of a
base to give the corresponding imidazole derivative.[5]
When imine 13c, chosen as a model compound, was treated
with TosMIC (1.5 equiv.) in MeOH and subsequently with
tBuNH2 (2.0 equiv., 20 °C) and stirred for 14 h at 50 °C (Table 2
entry 1), the desired imidazole 14c could be obtained, yet only
in a yield of 29 %. Upon extension of the reaction time to 96 h,
the yield rose to moderate 49 % (Table 2, entry 2). Assuming
Table 2. Optimization of the synthesis of imidazole 14c.
Entry TosMIC [equiv.] base [equiv.] 15 [equiv.] t [h] Isol. Yield [%]
1 1.5 tBuNH2 (2) 0 14 29
2 1.5 tBuNH2 (2) 0 96 49
3 1.5 tBuNH2 (6) 0 14 19
4 3.0 tBuNH2 (4) 0 14 37
5 n.d.[a] tBuNH2 (2) n.d.[a] 14 40
6 1.5 tBuNH2 (2) 3 14 44
7 1.5 tBuNH2 (6) 3 14 91
8 1.5 nBuNH2 (6) 3 14 48
9 1.5 DBU (6) 3 14 84
[a] The exact amount of TosMIC and 15 employed is unknown as a partially decomposed sample of TosMIC (the amount formally corresponding to 1.5 equiv.)
containing also 15 was used. 1H NMR spectroscopy indicated the amount of TosMIC in the mixture to be ca. 1/3 that of 15 ca. 2/3.
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that an increased amount of deprotonated TosMIC might raise
the reaction rate thus reducing the required reaction time, in a
next attempt 6 equivalents of the base were employed under
otherwise identical reaction conditions (50 °C, 14 h). However,
the amount of formed product 14c dropped to 19 % (Table 2,
entry 3) indicating that a higher concentration of the base had
an adverse effect. Therefore, the original ratio of TosMIC to
tBuNH2 of 1.5:2 was restored and the amount of TosMIC and
tBuNH2 relative to imine 13c was doubled (Table 2, entry 4).
This led to an improved, but still mediocre yield of 37 %
(Table 2, entry 4). To our surprise, when the reaction was carried
out with another batch of TosMIC under the initial reaction con-
ditions (1.5 equiv. TosMIC, 2 equiv. tBuNH2, 14 h), the yield im-
proved from 29 % to 40 % (Table 2, compare entries 5 and 1).
Careful analysis of the batch of TosMIC employed in this reac-
tion revealed that about 2/3 of the reagent had undergone
conversion into N-(tosylmethyl)formamide (15) by addition of
water and only 1/3 of the reagent had remained unchanged.
This result suggested that N-(tosylmethyl)formamide (15) has a
positive effect on the imidazole formation given the fact that
the actual quantity of TosMIC utilized was only about 1/3 of the
calculated 1.5 equiv. whereas the yield of imidazole 14c was
still higher than that for the reaction with pure TosMIC (Table 2,
compare entries 5 and 1). Accordingly, at next an experiment
was performed which was identical with the first reaction
(Table 2, entry 1) with pure TosMIC (1.5 equiv.) except that in
addition 3 equiv. of N-(tosylmethyl)formamide (15) were added
prior to heating to 50 °C for 14 h (Table 2, entry 6). In this
case, a yield of 44 % was reached for imidazole 14c which was
significantly better than the result of the original reaction with-
out N-(tosylmethyl)formamide (15), (Table 2, entry 1) and simi-
lar to that performed with the impure TosMIC sample (Table 2,
entry 5). Although the amount of TosMIC and N-(tosylmethyl)-
formamide (15) had notably been raised as compared to the
formerly conducted experiment (Table 2, compare entries 5 and
6), the yield remained roughly unchanged. Hence, it seemed
reasonable that the effect mediated by N-(tosylmethyl)form-
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present. Therefore, the last reaction (Table 2, entry 6) was re-
peated with 6 instead of 3 equivalents of tBuNH2 with the other
reaction conditions remaining unchanged. In that case
(1.5 equiv. TosMIC, 3 equiv. formamide 15, 6 equiv. tBuNH2),
imidazole 14c was isolated in an excellent yield of 91 %, sug-
gesting that for the positive effect of formamide 15 on the
imidazole formation indeed a sufficient amount of the base is
required. Thus, in this reaction, the base tBuNH2 might not only
be required for the deprotonation of the cycloaddition reagent
TosMIC, but also for a so far unknown activation of form-
amide 15.
To verify whether other bases also might be suitable for this
reaction, tBuNH2 was substituted by n-butylamine or by
1,8-diazabicyclo(5.4.0)undec-7-ene (DBU) (Table 2, entries 8–9).
With nBuNH2, the yield significantly decreased to only 48 %,
whereas DBU proofed to be a suitable base as well and a very
good yield (84 %) was achieved. However, as it is known that
TosMIC does not decompose in the presence of tBuNH2[5] and
the best yield in our experiments was obtained with this base,
tBuNH2 was chosen as base for all future experiments. Next, for
the so far developed reaction conditions, 1H NMR experiments
were performed in the presence of 1,3,5-trimethoxybenzene as
internal standard over a period of 20.5 h (Figure 3, solid line) to
get an estimate in what quantity the starting material 13c is
consumed and the product 14c is formed.
Figure 3. Time course of the imidazole formation in the absence and in the
presence of N-(tosylmethyl)formamide (15). The percentage of 13c and [2H2]-
14c in the reaction mixture was determined by 1H NMR spectroscopy apply-
ing 1,3,5-trimethoxybenzene as internal standard.
Because of the need of (2H4)CH3OH as a deuterated solvent,
these 1H NMR experiments, however, did not reflect the signals
of TosMIC, but of its deuterated analogue [2H2]-TosMIC (ex-
change of protons of CH2 group) and finally also those of the
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double deuterated form of the final product, [2H2]-14c. In case
of the reaction of 13c with TosMIC in the presence of N-(tosyl-
methyl)formamide (15), the percentage of the product [2H2]-
14c was fast-growing. An amount of 47 % and 76 % had been
reached after 0.5 h and 1.5 h, respectively thereafter it took
19 h to further raise to 88 % (after 20.5 h). Interestingly, the
share of remaining imine 13c had dropped within 0.5 h to a
value as low as 11 %. Thereafter, it lowered to 4 % within a
reaction time of 2.5 h from whereon no further significant
change could be observed. Due to the fact that a good 1H NMR
yield for imidazole [2H2]-14c could already be observed after a
reaction time of 1.5 h, this reaction time was considered suffi-
cient for any further reaction to be performed.
In contrast, the reaction of imine 13c with [2H2]-TosMIC to
give imidazole [2H2]-14c performed in the absence of forma-
mide 15 (Figure 3, dashed line) proceeded much slower. After
1.5 h, just 4 % of imidazole [2H2]-14c had formed. This amount
rose slowly to 51 % within 48 h, which equals the quantity that
had been reached within only 0.5 h in the prior experiment
with formamide 15, clearly demonstrating the promoting effect
of this compound (15). Intriguingly, in case of the cycloaddition
reaction of 14c with TosMIC executed in the presence of forma-
mide 15, a large gap between the amount of remaining start-
ing material 13c and formed product [2H2]-14c exists, the sum
of the share of both compounds being distinctly below 100 %.
This phenomenon was most pronounced at the beginning of
the reaction and became continuously less with increasing reac-
tion time. In the absence of formamide 15, no such discrepancy
could be observed (see Figure 3). This clearly points to the
formation of some intermediate during the reaction performed
in the presence of N-(tosylmethyl)formamide (15), though at
this point due to the complexity of the 1H NMR spectra no such
compound could be identified.
Next, the reaction conditions established for the cycloaddi-
tion of 13c with TosMIC in the presence of N-(tosylmethyl)-
formamide (15) were applied to the tricyclic imines 13a–13b
and 13d–13f. In order to get insight in the promoting effect of
N-(tosylmethyl)formamide (15), these reactions were also per-
formed in the absence of N-(tosylmethyl)formamide (15).
In both cases, the consumption of imine and formation of
imidazole was quantified directly by 1H NMR at the time point
given. For this reason, the reactions were carried out in
(2H4)CH3OH again. When imine 13a was treated with TosMIC
(1.5 equiv.) in the presence of formamide 15 (3 equiv.) and
tBuNH2 (6 equiv.) for 1.5 h at 50 °C, the desired imidazole [2H2]-
14a was formed to 51 % with no imine 13a remaining (Table 3,
entry 1). When in the same reaction formamide 15 was omitted,
the 1H NMR yield of imidazole [2H2]-14a dropped to 25 %, and
45 % of the starting material 13a was found to be still present.
The results obtained for the reactions of imines 13b–13d with
TosMIC leading to [2H2]-14b–14d (for the sake of completeness
data of the formation of [2H2]-14c described above have been
included here, too) highlight the positive effect of N-(tosyl-
methyl)formamide (15) even better. Thus, the yields for imidaz-
oles [2H2]-14b–14d amounted to 46–76 % when formamide 15
was present, whereas only negligible amounts were identified
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Table 3. Synthesis of various imidazoles.
[a] The amount of 13 and 14 in the crude reaction mixture was determined using 1H NMR spectroscopy with 1,3,5-trimethoxybenzene as internal standard.
[b] Isolated yield after purification (given in parentheses). The experiment was carried out in non-deuterated methanol leading to a non-deuterated imidazole.
[c] Identical to data given in Figure 3; isolated yield identical to data given in Table 2. [d] Yield determined after aqueous workup (addition of
1,3,5-trimethoxybenzene as internal standard to the crude reaction mixture, evaporation of (2H4)CH3OH, redissolving in CH2Cl2 and twofold washing with
brine) using 1H NMR spectroscopy. [e] In consequence of the low yields obtained, only analysis by 1H NMR and ESI-HRMS was conducted for these products.
[f ] Reaction at 25 °C.
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imines 13b-d, remained unchanged (Table 3, entries 2–4). To
ensure that the moderate 1H NMR yields for the syntheses of
imidazoles [2H2]-14a–14b,d in the presence of 15 were not due
to an insufficient reaction time, these were repeated, setting
the reaction time to 3 h. Yet, the quantities for unreacted
imines 13a–13b,d and formed imidazoles [2H2]-14a–14b,d re-
mained virtually unchanged (Table 3, entries 1, 2 and 4) which
is in line with what had been observed when studying the time
course of the transformation of 13c into [2H2]-14c (Figure 3).
Similar to this transformation described in Figure 3, also the
sum of the quantities of unreacted imine and formed imidazole
was distinctly lower than 100 %, in particular for the transfor-
mations of imines 13a–13b into imidazoles [2H2]-14a–14b. Re-
markably, when the synthesis of imidazoles 14a–14d was car-
ried out in non-deuterated methanol (in the presence of 15),
the yields achieved after purification for the, in consequence
non-deuterated imidazoles 14a–14d were higher (56–91 % vs.
46–76 %; see Table 3, entries1–4) than those observed in the
1H NMR experiments [in (2H4)CH3OH] afore. This is likely to be
attributed to a so far unknown precursor of 14a–14d which
upon workup is at least partially transformed in the respective
imidazole derivative. This was exemplarily verified by subjecting
the 1H NMR experiment with imidazole [2H2]-14d (reaction
time 1.5 h) to an aqueous workup. Thereupon, the yield for
[2H2]-14d determined by 1H NMR out of the crude reaction
Figure 4. X-ray crystal structures of imidazole 14d and tricyclic imines 13b, 13d and 13f.[17]
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product rose from 48 % to 59 %, now being in good accord
with the isolated yield of 56 % (Table 3, entry 4). By crystalliza-
tion and subsequent X-ray crystallography of the non-deuter-
ated imidazole 14d the unique structure of these imidazoles
was corroborated (Figure 4).
In contrast to the results described above, the yields ob-
tained in the syntheses of imidazoles [2H2]-14e–f from imines
13e–13f were quite disappointing. Monitoring the reactions by
TLC revealed that within 1.5 h no detectable amount of product
had formed independent of the absence or presence of forma-
mide 15. When the reaction time was extended to 6 d for the
formation without N-(tosylmethyl)formamide (15), still only
minute amounts of imidazole derivatives [2H2]-14e–14f could
be detected (ca. 2 %, Table 3, entries 5–6). In contrast, the yield
for these compounds was distinctly higher when formamide 15
was present in the reaction mixture, though still low with values
of 14 % and 12 % for [2H2]-14e and [2H2]-14f, respectively.
Hence, despite the poor outcome of these reactions, the posi-
tive effect of formamide 15 was still clearly evident.
The poor yields obtained for the cycloaddition reaction per-
formed with the cyclic imines 13e–13f appear quite astonish-
ing, considering the close structural similarity of these com-
pounds with the imines 13a–13d, for which the yields for the
cycloaddition products, the imidazole derivatives [2H2]-14a–
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be associated with the continuous enlargement of the “upper
bridge”, from a CH2, to a CH2CH2, and finally a CH2CH2CH2 unit
upon the transition from 13a–13b to 13c–13d and finally to
13e–13f. As a result of the increasing size of this bridge, the
adjacent bridgehead substituents should be pushed towards
the imine function, thus increasing the shielding and associated
with that reducing the reactivity of the latter. The assumed
change of the orientation of the aforementioned bridgehead
substituents could be verified by X-ray structures obtained for
the phenyl-substituted imines 13b, 13d, and 13f. These clearly
show that with the increasing size of the “upper bridge” the
bridgehead substituents are getting closer to the imine func-
tion.
Finally, the effect of N-(tosylmethyl)formamide (15) on the
cycloaddition reaction of imines 13a–13f with TosMIC should
exemplarily also be studied for some imines structurally differ-
ent from 13a–13f. As such 2,3,4,5-tetrahydropyridine (13g) and
3,4-dihydroisoquinoline (13h) were selected. In case of the reac-
tion with imine 13g, the starting material was fully consumed
within 1.5 h, independent of whether formamide 15 was
present or not. However, this time the yield of the cycloaddition
product [2H2]-14g was higher when 15 was absent (41 %) than
when it was present (21 %). Possibly, formamide 15 mediates
decomposition reactions in this case as a multitude of side
products was detected by 1H NMR, which might be associated
with the dynamic character of imine 13g existing in mono- and
trimeric form.[18] However, the positive effect of N-(tosyl-
methyl)formamide (15) in the cycloaddition reaction with Tos-
MIC became again evident when 3,4-dihydroisoquinoline (13h)
was used as starting material. Employing the standard condi-
tions, the 1H NMR yield for the product [2H2]-14h amounted to
83 % when formamide 15 was present and to 66 % when it was
absent. Thereby, according to the 1H NMR data in the first case
the starting material had been completely consumed (0 %, 13h)
and in the latter 25 % remained unchanged (reaction time
1.5 h). The positive effect of N-(tosylmethyl)formamide (15) be-
came even more apparent, when the conversion of imine 13h
into [2H2]-14h was performed at a reduced temperature of
25 °C instead of 50 °C. Then, after the same reaction time (1.5 h)
only 23 % of the imine 13h had been transformed into product
[2H2]-14h when 15 was absent, but 86 % in its presence
(1H NMR yields, Table 3, entry 8).
Next, to shed some light on the fate and possibly on the
function of N-(tosylmethyl)formamide 15 in the above de-
scribed cycloaddition reaction, a series of control experiments
was performed. First, formamide 15 dissolved in (2H4)CH3OH
was kept for 1.5 h at 50 °C in the absence of any additive and
further in the presence of TosMIC (0.5 equiv.), tricylic imine 13c
(0.33 equiv.), or tBuNH2 (2.0 equiv.) (Table 4, entries 1–4). Ac-
cording to the subsequently performed 1H NMR analysis of the
respective reactive mixtures, formamide 15 remained com-
pletely unchanged when no additive or TosMIC was present, or
was accompanied with minute amounts of the decomposition
product 16 (ca. 1 %; 16 was identified in a subsequent reaction)
when tricyclic imine 13c was present. However, when tert-butyl-
amine was added (Table 4, entry 4) only minor amounts of 15
(4 %) remained unchanged after 1.5 h and new species had
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formed. One of these could be identified as p-toluenesulfinic
acid 16, the share of which amounted to 96 %. Thereby, the
base-induced decomposition of formamide 15 proceeds rather
fast, as about 35 % of this compound had been converted into
p-toluenesulfinic acid 16 even at the lower temperature of 25 °C
within 7 min (Table 4, entry 5).
Table 4. Reactions of N-(tosylmethyl)formamide 15 under varying conditions.
To check whether TosMIC or imine 13c might influence the
tBuNH2 induced decomposition of formamide 15, control ex-
periments were performed, in which in addition to tBuNH2 ei-
ther TosMIC or imine 13c was present (Table 4, entries 6–7). The
decay of formamide 15 turned out to be largely independent
from these additives. However, new signals appeared in the
1H NMR spectra (as compared to the reactions without these
additives) indicating that from 15 derived decomposition prod-
ucts might have reacted with TosMIC and tricyclic imine 13c,
respectively. Yet, attempts to identify the newly formed species
remained unsuccessful due to the high complexity of the 1H
NMR spectra and the low amounts of the respective com-
pounds present.
According to Xia et al.,[19] N-(tosylmethyl)formamide (15)
upon treatment with Cs2CO3 (in toluene, at 70 °C) undergoes a
decomposition reaction yielding p-toluenesulfinate 16 and
N-methyleneformamide (17). Thereby the formation of the lat-
ter had only become evident from a by-product that had
formed via its participation in a Michael addition reaction.
Hence, it seemed reasonable to assume that also upon treat-
ment of formamide 15 with tBuNH2 (as it is e.g. the case in the
reaction listed in Table 4, entry 4) besides p-toluenesulfinate
(16) also N-methyleneformamide (17) is generated, though also
as a rather short-lived intermediate.
A first hint that N-methyleneformamide 17 may also have
formed under the reaction conditions used for the cycloaddi-
tion of imines 13 with TosMIC, i.e. when tBuNH2 in (2H4)CH3OH
is applied as a base, came from an MS analysis (ESI-HRMS, see
SI). A reaction product obtained by treatment of imine 13c with
formamide 15 and tBuNH2 (Table 4, entry 7) showed a MS
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Next, tBuNH2 should be substituted by Cs2CO3 in the cyclo-
addition reactions of imine 13c with TosMIC. That way, so our
hope, consecutive reactions of N-methyleneformamide (17)
might be shifted towards intermediates important for the cyclo-
addition reaction with TosMIC, as no competing reactions with
tBuNH2 as nucleophile could take place.
A control experiment performed in this context, in which
N-(tosylmethyl)formamide 15 was treated with Cs2CO3 in
(2H4)CH3OH at 25 °C, revealed that also under these reaction
conditions and within 20 min, 15 is almost quantitatively trans-
formed in p-toluenesulfinic acid salt 16 (Table 4, entry 8).
Though still no evidence for the formation of N-methylene-
formamide (17) was found. However, when the decomposition
experiment of N-(tosylmethyl)formamide 15 by Cs2CO3 in
(2H4)CH3OH at 25 °C was performed in the presence of im-
ine 13c (Scheme 1), a new compound could be detected and
isolated. This compound could be identified as the dimer 18[20]
the structure of which comprising a unique 1,3,5,7-tetrazoctane
ring could be unequivocally established by X-ray crystallogra-
phy (Figure 5). As can be seen from the structure of dimer 18,
this compound is the result of the combination of two mol-
ecules of the tricyclic imine 13c with two molecules of
N-methyleneformamide 17. Accordingly, upon decomposition
of formamide 15 besides p-toluenesulfinic acid 16 (compare to
Table 4, entry 8), N-methyleneformamide 17 must have formed.
Still, the existence of N-methyleneformamide 17 itself could not
be corroborated, which might indicate that it is prone to rapid
consecutive reactions under the reaction conditions given.
Interestingly, later on dimer 18 (and what is thought to be
its racemic diastereomer rac-18a) could also be identified in the
1H NMR spectra of experiments performed before (see support-
Scheme 1. Cs2CO3-induced decomposition of N-(tosylmethyl)formamide 15 in presence of imine 13c.
Figure 5. X-ray crystal structure of dimer 18.[17]
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ing information). In particular, these were the control experi-
ment when the decomposition of formamide 15 by tBuNH2 had
been studied in presence of imine 13c (Table 4, entry 7) as well
as the experiments in which the reactions time course under
the original reaction conditions had been monitored by 1H NMR
(Figure 3, reaction with N-(tosylmethyl)formamide 15; NMR
taken after 0.5 h). Obviously also tBuNH2 similar to Cs2CO3 ap-
pears to lead to the formation of N-methyleneformamide 17
upon fragmentation of N-(tosylmethyl)formamide (15).
Based on the above described results, the following mecha-
nism for the catalytic effect of N-(tosylmethyl)formamide 15 on
the synthesis of imidazoles seems plausible (Scheme 2). In the
first step, N-(tosylmethyl)formamide (15) is cleaved by tert-but-
ylamine to give p-toluenesulfinic acid 16 besides N-methylene-
formamide 17. By acting as a Michael acceptor methylene-
formamide 17 reacts with imine 13c to the iminium ion 19,
which exists in a reversible equilibrium with the isolated
dimer 18 (and rac-18a) which has been isolated. Then TosMIC
adds to this derivative, the thus activated intermediate iminium
ion 19 – which possibly exists in an equilibrium with a cyclic
oxadiazene species – to give the addition product 20. Retro-
Michael addition releases N-methyleneformamide 17 which is
now available for a new reaction cycle. The nitrogen centered
anion 21 that has been liberated by the retro-Michael addition
should then successively react to imidazole 14c, as it has been
proposed by van Leusen et al. for the formation of imidazoles
from imines and TosMIC, where a species analogous to 21 has
been postulated as primary addition product.[5] According to
this rationale, N-methyleneformamide 17 acts as a catalyst for
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Scheme 2. Rationale for the promoting effect of N-(tosylmethyl)formamide (15).
Finally, to ensure the promoting effect for the imidazole syn-
theses arises from N-methyleneformamide 17 and not from an-
other decomposition product of N-(tosylmethyl)formamide 15,
p-toluenesulfinic acid 16 and the most obvious hydrolysation
products of N-methyleneformamide (17), i.e. formaldehyde and
formamide, were studied for their effects on the formation of
imidazole 14c under the standard conditions (Table 5, entries
1–3). None of the tested compounds led to a reasonable effect
and the starting imine 13c remained largely unchanged. Inter-
estingly, also the attempt to mimic the function of N-methyl-
eneformamide 17 with acrolein in the course of the imidazole
synthesis proved to be unsuccessful (Table 5, entry 4). As it
seems, acrolein, due to its high reactivity, is prone to extensive
side reactions leading to consumption of starting material 13c
and of TosMIC, that way interfering with the formation of the
desired imidazole 14c. This highlights nicely the unique func-
tion of N-methyleneformamide 17 as a catalyst that activates
the imine function in the van Leusen imidazole synthesis.
Table 5. Control experiments to affirm N-methyleneformamide (17) as cata-
lyst.
[a] The amount of 13c and [2H2]-14c in the crude reaction mixture was deter-
mined using 1H NMR spectroscopy with 1,3,5-trimethoxybenzene as internal
standard.
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Conclusion
In summary, a small set of imidazoles fused with a cyclic system
in 1- and 5-position, starting from saturated aliphatic tricycles
incorporating an imine functional group and TosMIC has been
synthesized. By serendipity, N-(tosylmethyl)formamide was
identified as a pre-catalyst for the imidazole synthesis, leading
to significantly increased yields and shortened reaction times.
Mechanistic studies suggest that by a tert-butylamine induced
decomposition of N-(tosylmethyl)formamide, N-methylene-
formamide is generated. Being a Michael acceptor, N-methyl-
eneformamide (17) acts as an organocatalyst of these reactions
by reacting with the imines, thus forming the corresponding
iminium ions 19, that are activated for the nucleophilic attack
by TosMIC. This appears to be the first time an activation of
imines for imidazole synthesis via cycloaddition with TosMIC
is described which is likely to possess great potential for the
employment of less reactive imines for the construction of
1,5-disubstituted imidazoles via the van Leusen imidazole syn-
thesis. Accordingly, further studies exploring the scope of this
method, the use of methyleneformamide (17) as an organocat-
alyst on an expanded set of acyclic and cyclic imines in the
van Leusen imidazole synthesis can be expected to become a
rewarding endeavor.
Experimental Section
Anhydrous reactions were performed under an argon atmosphere
in vacuo-dried glassware. All solvents were distilled prior to use
and dry THF, Et2O, 1,4-dioxane and CH2Cl2 were prepared under a
nitrogen atmosphere according to standard procedures.[21] All pur-
chased chemicals were used without further purification. TLC was
performed with plates from Merck KGaA (silica gel 60 F254 or alumi-
num oxide 60 F254 on aluminum sheets, neutral). For purification
via flash chromatography (FC) silica gel 60 (40–63 μm mesh size)
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mesh size) from Sigma-Aldrich adjusted to Brockmann III activity
grade[22] prior to use were employed. Melting points were deter-
mined with a BÜCHI 510 melting point apparatus. All melting points
are uncorrected. Infrared spectra were recorded with a Perkin Elmer
Paragon 1000 and a Jasco FT/IR-410. Solid substances were meas-
ured as KBr pellets and oils as film on NaCl. HRMS were obtained
with a Finnigan MAT 95 (EI) and a Finnigan LTQ FT (ESI). 1H and 13C
NMR spectra were acquired with a Avance III HD Bruker BioSpin
(400 or 500 MHz), referenced to the solvent residual peak as internal
standard and analyzed with MestReNova (Version 12.0.0–20080;
Mestrelab Research S.L.; released 26.09.2017).[23]
2,3,4,5-Tetrahydropyridine 13g[24] and N-(tosylmethyl)form-
amide 15[19] were synthesized according to the literature.
Synthesis of 4,4-disubstituted N-triisopropylsilyl-1,4-dihydro-
pyridines (general procedure/ GP1)
The 4-substituted pyridine derivatives were dissolved in CH2Cl2
(0.86 mL/mmol) and TIPSOTf (1.1 equiv.) was added. Prior to cooling
to –30 °C and subsequent dropwise addition of the R2Mg solution
(0.55 equiv.) the solution was stirred at r.t. for 15 min. After the time
given the reaction was quenched by addition of water (10 mL/
mmol) followed by extraction of the aqueous layer with CH2Cl2 (3 ×
10 mL/mmol). The combined organic layers were dried with MgSO4
and the solvent was removed under vacuum. Quantitative determi-
nation of the dihydropyridines in the crude product was achieved
by 1H NMR spectroscopy using 2,4,6-collidine as internal standard.
The oxidation of side products was realized by stirring of the crude
product under air for the specified period of time, followed by puri-
fication by FC.
Synthesis of symmetric tricyclic imines (general procedure / GP2)
The symmetric tricyclic imines were prepared in analogy to the liter-
ature.[14a]
TFA (15 equiv.) was added to a solution of the 4,4-disubstituted N-
triisopropylsilyl-1,4-dihydropyridine (1.0 equiv.) in pentane (10 mL/
mmol) in one portion and the resulting mixture was stirred for
15 min at 20 °C. The reaction was quenched by the addition of
K2CO3 (8 equiv.) and a 1:1 mixture of 2 M HClaq. and EtOH (40 mL/
mmol) was added. The solution was washed with pentane (6 ×
20 mL/mmol) and adjusted to pH = 9 with K2CO3. The aqueous
layer was extracted with CH2Cl2 (4 × 20 mL/mmol), the organic lay-
ers were combined, dried with Na2SO4, and the solvent was re-
moved under vacuum. The crude product was purified by FC.
Synthesis of symmetric tricyclic imidazoles (general procedure /
GP3)
To a solution of TosMIC (1.5 equiv.) in methanol (6.7 mL/mmol)
the imine (1.0 equiv.) and subsequently N-(tosylmethyl)formamide
(3 equiv.) was added at 20 °C. The resulting mixture was treated
with tBuNH2 (6 equiv.), stirred for 1.5 h at 50 °C and then allowed
to reach 20 °C. The solvent was removed under vacuum, the residue
was dissolved in CH2Cl2 (20 mL/mmol) and washed with saturated
aqueous NaCl solution (20 mL/mmol) twice. The organic layer was
dried with MgSO4, the solvent removed under vacuum and the
crude product was purified by FC.
NMR experiments
The 1H NMR experiments to study the formation of the imidazoles
(Figure 3; Table 3, Table 5) and to explore the function of N-(tosyl-
methyl)formamide 15 (Table 4; Scheme 1) were carried out on the
basis of GP3 in (2H4)CH3OH. The concentrations of the reagents
used were identical to those described in GP3 and as follows: Imines
13a–13h (0.1 mmol/mL), TosMIC (0.15 mmol/mL), N-(tosyl-
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methyl)formamide 15 (0.3 mmol/mL), tBuNH2 (0.6 mmol/mL). After
the reaction time indicated the crude reaction mixtures were cooled
to 20 °C and analyzed by 1H NMR spectroscopy. Quantification of
the imines 13a–13h and the imidazoles 14a–14h in the crude reac-
tion mixture was achieved by 1H NMR spectroscopy with 1,3,5-tri-
methoxybenzene as internal standard. Assignment of the imine and
imidazole protons was accomplished by means of reference spectra
given in this publication or in literature.
Preparation of bis(organo)magnesium solutions 10c–f
The bis(organo)magnesium solutions employed in the synthesis of
the 4,4-disubstituted N-triisopropylsilyl-1,4-dihydropyridines were
prepared according to our previously published procedure.[14a] The
utilized organic halides (3-bromoprop-1-en-2-yl)benzene,[25] 4-
bromo-2-methylbut-1-ene,[26] 1-bromo-3-phenylbut-3-ene[27] (syn-
thesis via 3-phenylbut-3-en-1-ol[28]), 5-bromo-2-methylpent-1-ene[29]
and (5-chloropent-1-en-2-yl)benzene[30] were synthesized according
to literature. 3-Bromo-2-methyl-1-propene was purchased.
Magnesium turnings (1.5 equiv.) were covered with THF (0.13 mL/
mmol) and a solution of the organic halide (1.0 equiv.) in THF
(0.8 mL/mmol) was added dropwise to keep the reaction mixture
boiling mildly. After complete addition stirring was continued for
1 h at 20 °C followed by addition of 1,4-dioxane (1.1 equiv.) and
further stirring for 1 h at 20 °C. The resulting suspension was centri-
fuged (30 min, 3000 g), the supernatant was separated and the
remaining slurry was suspended in Et2O to retrieve the same vol-
ume as before. Centrifugation was repeated (30 min, 3000 g) and
the supernatants were combined. The concentrations of the bis-
(organo)magnesium solutions were determined according to a pro-
cedure of Chong et al.[31]
Deviating from this, bis(2-methylallyl)magnesium 10a and bis(2-
phenylallyl)magnesium 10b were synthesized as reported below.
Bis(2-methylallyl)magnesium 10a
3-Bromo-2-methylpropene (1.0 equiv., 2 M in THF) was added to
magnesium powder (1.2 equiv., 3 M in THF) over a period of 2 h at
0 °C. The reaction mixture was kept at 0 °C for 2 h, subsequently
stirred at 20 °C for 12 h followed by addition of 1,4-dioxane
(1.1 equiv.) and further stirring for 1 h at 20 °C. The resulting sus-
pension was centrifuged (30 min, 3000 g), the supernatant was sep-
arated and the remaining slurry was suspended in Et2O to retrieve
the same volume as before. Centrifugation was repeated (30 min,
3000 g) and the supernatants were combined.
Bis(2-phenylallyl)magnesium 10b
To a suspension of Rieke magnesium (preparation in analogy to
literature;[32] 0.57 M in THF; 1 equiv.) was added (3-bromoprop-1-
en-2-yl)benzene (0.40 equiv.) dropwise. The mixture was kept at
20 °C for 1 h followed by addition of 1,4-dioxane (0.55 equiv.) and
further stirring for 1 h at 20 °C. The resulting suspension was centri-
fuged (30 min, 3000 g) and the supernatant was separated.
4-Methyl-4-(2-methylallyl)-1-triisopropylsilyl-1,4-dihydro-
pyridine 11a
Synthesis according to GP1 from 4-picoline (305 mg, 3.27 mmol,
318 μL), TIPSOTf (1.10 g, 3.59 mmol, 0.97 mL) and bis(2-methyl-
allyl)magnesium 10a (0.09 m in THF/Et2O 1:1, 1.80 mmol, 20.0 mL).
The reaction was stopped after 16 h. Quantitative determination
indicated 590 mg (59 %) of dihydropyridine 11a followed by stirring
under air for 2 d. Purification by FC (Al2O3-basic, activity III, pentane)
afforded 11a.
Co l o r l e s s o i l ( 5 5 2 m g, 5 5 % ) ; R f = 0 . 9 5 (A l 2 O 3 ; p e nt a n e );
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4.76 (dq, J = 2.9/1.5 Hz, 1 H, CCH2CCH2b), 4.66–4.61 (m, 1 H,
CCH2CCH2a), 4.29 (d, J = 8.2 Hz, 2 H, 2 × NCHCH), 1.97 (d, J = 0.7 Hz,
2 H, CCH2C), 1.77 (dd, J = 1.4/0.8 Hz, 3 H, CH2CCH3), 1.30–1.18 (m,
3 H, 3 × CH(CH3)2), 1.07 (d, J = 7.2 Hz, 18H, 3 × CH(CH3)2), 1.05 (s,
3 H, CHCCH3); 13C NMR (100 MHz, CDCl3): δ = 144.6 (CHCCH2C),
127.5 (NCH), 113.1 (CCH2CCH2), 108.6 (NCHCH), 53.9 (CHCCH2), 34.4
(CHC), 34.2 (CHCCH3), 25.0 (CHCCH2CCH3), 18.0 (3 × CH(CH3)2), 11.6
(3 × CH(CH3)2); IR (film): ν̃ = 3072, 3043, 2945, 2868, 1670, 1601,
1464, 1369, 1288, 1088, 1065, 1016, 970, 883, 733, 689, 660 cm–1;
HRMS (EI): m/z [M]+ calcd. for C19H35NSi: 305.2533, found 305.2583.
4-Phenyl-4-(2-phenylallyl)-1-triisopropylsilyl-1,4-dihydro-
pyridine 11b
Synthesis according to GP1 from 4-phenylpyridine (1.38 g,
8.89 mmol), TIPSOTf (3.00 g, 9.78 mmol, 2.6 mL) and bis(2-phenyl-
allyl)magnesium 10b (0.10 m in THF, 4.89 mmol, 50.0 mL). The reac-
tion was stopped after 16 h. Quantitative determination indicated
996 mg (26 %) of dihydropyridine 11b followed by stirring under
air for 2 d. Purification by FC (Al2O3-basic, activity III, pentane) af-
forded 11b.
Orange solid (723 mg, 19 %); Rf = 0.41 (Al2O3; pentane); m.p. 59 °C;
1H NMR (400 MHz, CDCl3): δ = 7.43–7.38 (m, 2 H, 2 × CHCCCHCHCH),
7.35–7.28 (m, 4 H, 2 × CHCCCHCHCH, 2 × CalkeneCCH), 7.25–7.16 (m,
3 H, 2 × CalkeneCCHCH, CalkeneCCHCHCH), 7.13 (tt, J = 7.3/1.2 Hz, 1 H,
CHCCCHCHCH), 5.89 (d, J = 8.2 Hz, 2 H, 2 × NCH), 5.28 (d, J = 1.9 Hz,
1 H, CCH2CCH2b), 5.03–4.98 (m, 1 H, CCH2CCH2a), 4.35 (d, J = 8.3 Hz,
2 H , 2 × N C H C H ) , 2 .9 9 ( s, 2 H, CC H 2 C ) , 1 .2 7– 1. 13 (m , 3 H,
3 × C H ( C H 3 ) 2 ) , 1 . 0 5 ( d , J = 7 . 2 H z , 1 8 H , 3 × C H ( C H 3 ) 2 );
13C NMR (100 MHz, CDCl3): δ = 152.5 (CHCCCHCHCH), 147.0
(CalkeneCCH), 144.0 (CalkeneCCH), 128.2 (CHCCCHCHCH), 127.9
( C a l k e n e C C H C H ) , 1 2 7 . 7 ( N C H ) , 1 2 7 . 1 ( C a l k e n e CC H ) , 1 2 6 . 7
(CalkeneCCHCHCH), 126.6 (CHCCCHCHCH), 125.3 (CHCCCHCHCH),
116.7 (CCH 2 CC H 2 ) , 106.7 (NCHC H), 49.0 (CC H 2 CCH 2 ) , 42.8
(CCH2CCH2), 18.0 (3 × CH(CH3)2), 11.5 (3 × CH(CH3)2); IR (film): ν̃ =
3643, 3325, 3271, 3055, 3022, 2927, 2864, 1946, 1871, 1803, 1599,
1495, 1444, 1032, 758, 700 cm–1; HRMS (ESI): m/z [M + H]+ calcd.
for C29H40NSi 430.2925, found 430.2926.
4-Methyl-4-(3-methylbut-3-en-1-yl)-1-triisopropylsilyl-1,4-di-
hydropyridine 11c
Synthesis according to GP1 from 4-picoline (1.14 g, 12.3 mmol,
1.2 mL), TIPSOTf (4.14 g, 13.5 mmol, 3.6 mL) and bis(3-methylbut-
3-en-1-yl)magnesium 10c (0.25 m in THF/Et2O 1:1, 6.77 mmol,
27.0 mL). The reaction was stopped after 16 h. Quantitative determi-
nation indicated 1.57 g (40 %) of dihydropyridine 11c. Purification
by FC (Al2O3-basic, activity III, pentane) afforded 11c.
Colorless solid (1.45 g, 37 %); Rf = 0.97 (Al2O3; pentane); m.p. 33 °C;
1H NMR (400 MHz, CDCl3): δ = 6.03–5.96 (m, 2 H, 2 × NCH), 4.65 (q,
J = 1.1 Hz, 2 H, CH2CH2CCH2), 4.21–4.15 (m, 2 H, 2 × NCHCH), 2.04–
1.94 (m, 2 H, CHCCH2CH2), 1.72 (t, J = 1.0 Hz, 3 H, CalkeneCH3), 1.29–
1.18 (m, 5 H, 3 × CH(CH3)2, CHCCH2), 1.08 (d, J = 7.2 Hz, 18H,
3 × CH(CH3)2), 1.03 (s, 3 H, CHCCH3); 13C NMR (100 MHz, CDCl3):
δ = 147.8 (CH2CH2CCH3), 128.3 (NCH), 108.6 (CH2CH2CCH2), 107.8
(NCHCH), 44.0 (CHCCH2), 34.9 (CH2CH2CCH2), 33.8 (CHCCH3, CHC),
23.2 (CHC(CH2)2CCH3), 18.0 (3 × CH(CH3)2), 11.6 (3 × CH(CH3)2);
IR (KBr): ν̃ = 3091, 3041, 2945, 2866, 1668, 1647, 1599, 1464, 1377,
1286, 1109, 1078, 1045, 1016, 972, 881, 746, 733, 689, 663, 619,




Synthesis according to GP1 from 4-phenylpyridine (534 mg,
3.44 mmol), TIPSOTf (1.16 g, 3.78 mmol, 1.05 mL) and bis(3-phenyl-
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but-3-en-1-yl)magnesium 10d (0.20 m in THF/Et2O 1:1, 1.89 mmol,
9.6 mL). The reaction was stopped after 16 h. Quantitative determi-
nation indicated 1.01 g (66 %) of dihydropyridine 11d followed by
stirring under air for 4 d. Purification by FC (Al2O3-basic, activity III,
pentane) afforded 11d.
Yellow solid (788 mg, 52 %); Rf = 0.52 (Al2O3; pentane); m.p. 54 °C;
1H NMR (500 MHz, CDCl3): δ = 7.46–7.42 (m, 2 H, 2 × CalkeneCCH),
7 . 4 1 – 7 .3 8 ( m, 2 H, 2 × CH CCC H CH CH ) , 7 . 34 –7 .2 9 ( m, 4 H,
4 × CCCHCHCH), 7.27–7.23 (m, 1 H, CalkeneCCHCHCH), 7.14 (tt, J =
7.3/1.3 Hz, 1 H, CHCCCHCHCH), 6.19 (d, J = 8.3 Hz, 2 H, 2 × NCH),
5.31 (d, J = 1.4 Hz, 1 H, CH2CH2CCH2b), 5.11 (d, J = 1.4 Hz, 1 H,
CH2CH2CCH2a), 4.44 (d, J = 8.3 Hz, 2 H, 2 × NCHCH), 2.66–2.57 (m,
2 H, CH2CH2CCH2), 1.86–1.78 (m, 2 H, CH2CH2CCH2), 1.30 (sep, J =
7.5 Hz, 3 H, 3 × CH(CH3)2), 1.12 (d, J = 7.4 Hz, 18H, 3 × CH(CH3)2);
13C NMR (125 MHz, CDCl3): δ = 152.4 (CHCCCHCHCH), 149.5
(CalkeneCCH), 141.6 (CalkeneCCH), 128.5 (NCH), 128.3 (CCCHCHCH)*,
128.2 (CCCHCHCH)*, 127.3 (CalkeneCCHCHCH), 126.8 (CHCCCHCHCH),
126.2 (CalkeneCCH), 125.4 (CHCCCHCHCH), 111.6 (CH2CH2CCH2),
106.2 (NCHCH), 41.9 (CCH2CH2CCH2), 41.8 (CH2CH2CCH2), 32.4
(CH2CH2CCH2), 18.1 (3 × CH(CH3)2), 11.6 (3 × CH(CH3)2) Signals indi-
cated by * cannot be assigned unambiguously and are interchange-
able; IR (KBr): ν̃ = 3082, 3051, 2949, 2866, 1664, 1597, 1464, 1444,
1288, 1076, 1047, 976, 881, 777, 740, 692, 665, 632, 523, 498 cm–1;




Synthesis according to GP1 from 4-picoline (521 mg, 5.59 mmol,
0.54 mL), TIPSOTf (1.88 g, 6.15 mmol, 1.7 mL) and bis(4-methylpent-
4-en-1-yl)magnesium 10e (0.21 m in THF/Et2O 1:1, 3.07 mmol,
15.0 mL). The reaction was stopped after 18 h. Quantitative determi-
nation indicated 907 mg (49 %) of dihydropyridine 11e. Purification
by FC (Al2O3-basic, activity III, pentane) afforded 11e.
Co l o r l e s s o i l ( 9 3 5 m g, 5 0 % ) ; R f = 0 . 9 3 (A l 2 O 3 ; p e n t a n e);
1H NMR (500 MHz, CDCl3): δ = 6.00–5.95 (m, 2 H, 2 × NCH), 4.68–
4.61 (m, 2 H, CH2CH2CCH2), 4.20–4.13 (m, 2 H, 2 × NCHCH), 1.99 (t,
J = 7.6 Hz, 2 H, CH2CH2CCH2), 1.69 (s, 3 H, CalkeneCH3), 1.48–1.39 (m,
2 H, CH2CH2CH2), 1.28–1.18 (m, 3 H, 3 × CH(CH3)2), 1.14–1.03 (m,
2 H, CHCCH2), 1.08 (d, J = 7.4 Hz, 18 H, 3 × CH(CH3)2), 1.00 (s, 3 H,
CHCCH3); 13C NMR (125 MHz, CDCl3): δ = 146.8 (CH2CH2CCH3), 128.0
(NCH), 109.5 (CH2CH2CCH2), 108.1 (NCHCH), 45.6 (CHCCH2), 38.5
(CH2CH2CCH2), 33.8 (CHCCH3, CHC ), 24.3 (CH2CH2CH2), 22.6
(CalkeneCH3), 18.0 (3 × CH(CH3)2), 11.6 (3 × CH(CH3)2); IR (film): ν̃ =
3072, 3039, 2945, 2895, 2868, 1668, 1606, 1462, 1383, 1286, 1076,
1016, 970, 883, 731, 688, 665 cm–1; HRMS (EI): m/z [M – CH3]+ calcd.
for C20H36NSi 318.2612, found 318.2603.
4-Phenyl-4-(4-phenylpent-4-en-1-yl)-1-triisopropylsilyl-1,4-
dihydropyridine 11f
Synthesis according to GP1 from 4-phenylpyridine (818 mg,
5.27 mmol), TIPSOTf (1.78 g, 5.80 mmol, 1.56 mL) and bis(3-phenyl-
but-3-en-1-yl)magnesium 10f (0.19 m in THF/Et2O 1:1, 2.90 mmol,
15.5 mL). The reaction was stopped after 48 h. Quantitative determi-
nation was omitted followed by stirring under air for 2 d. Purifica-
tion by FC (Al2O3-basic, activity III, pentane) afforded 11f.
Yellow solid (1.31 g, 55 %); Rf = 0.63 (Al2O3; pentane); m.p. 61 °C;
1H NMR (500 MHz, CDCl3): δ = 7.41–7.35 (m, 4 H, 2 × CHCCCHCHCH,
2 × CalkeneCCH) 7.33–7.28 (m, 4 H, 4 × CCCHCHCH), 7.26–7.20 (m,
1 H, CalkeneCCHCHCH), 7.12 (tt, J = 7.3/1.3 Hz, 1 H, CHCCCHCHCH),
6.09–6.02 (m, 2 H, 2 × NCH), 5.25 (d, J = 1.5 Hz, 1 H, CH2CH2CCH2b),
5.06 (dt, J = 1.4/1.3 Hz, 1 H, CH2CH2CCH2a), 4.35–4.30 (m, 2 H,
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2 H, CH2CCH2CH2CH2), 1.61–1.54 (m, 2 H, CH2CH2CH2), 1.28–1.18 (m,
3 H, 3 × CH(CH3)2), 1.06 (d, J = 7.4 Hz, 18 H, 3 × CH(CH3)2);
13C NMR (125 MHz, CDCl3): δ = 152.7 (CHCCCHCHCH), 149.1
(CalkeneC), 141.9 (CalkeneC), 128.3 (CCCHCHCH)*, 128.1 (CCCHCHCH)*,
128.1 (NCH), 127.3 (CalkeneCCHCHCH), 126.8 (CHCCCHCHCH), 126.3
(CalkeneCCH), 125.3 (CHCCCHCHCH), 112.0 (CH2CH2CCH2), 106.5
(NCHCH), 41.8 (NCHCHC), 35.9 (CH2CH2CCH2), 24.8 (CH2CH2CH2),
18.0 (3 × CH(CH3)2), 11.5 (3 × CH(CH3)2) Signals indicated by * can-
not be assigned unambiguously and are interchangeable; IR (KBr):
ν̃ = 3049, 2949, 2864, 1666, 1626, 1601, 1491, 1460, 1387, 1288,
1078, 1057, 976, 883, 766, 744, 694, 665, 631 cm–1; HRMS (EI): m/z
[M]+ calcd. for C31H43NSi 457.3160, found 457.3170.
1,7-Dimethyl-4-azatricyclo[3.3.1.02,7]non-3-ene 13a
Synthesis according to GP2 from dihydropyridine 11a (622 mg,
2.04 mmol) and TFA (3.48 g, 30.5 mmol, 2.34 mL) in pentane
(20 mL). Purification by FC (Al2O3-basic, activity III, pentane/CH2Cl2/
MeOH 88.5:10:1.5) afforded imine 13a.
Yellow oil (230 mg, 76 %); Rf = 0.35 (Al2O3; pentane/CH2Cl2/MeOH
88.5:10:1.5); 1H NMR (400 MHz, CDCl3): δ = 8.08 (d, J = 3.8 Hz, 1 H,
NCHCH), 4.46 (tt, J = 3.1/1.9 Hz, 1 H, NCH(CH2)2), 2.48 (d, J = 3.7 Hz,
1 H, NCHCH), 1.71 (dt, J = 9.0/2.3 Hz, 1 H, CCH2bC), 1.58 (dd, J =
12.6/2.1 Hz, 2 H, 2 × NCHCH2b), 1.29 (d, J = 9.0 Hz, 1 H, CCH2aC),
0.94 (s, 6 H, 2 × CH3), 0.82–0.75 (m, 2 H, 2 × NCHCH2a); 13C
NMR (100 MHz, CDCl3): δ = 167.1 (NCHCH), 56.5 (NCH(CH2)2), 50.9
(NCHCH), 49.3 (CCH2C), 37.8 (NCH(CH2)2), 34.9 (CCH2), 26.6 (CH3);
IR (film): ν̃ = 3388, 2997, 2947, 2920, 2860, 1672, 1610, 1450, 1375,
1342, 1282, 1151, 1016, 719 cm–1; HRMS (EI): m/z [M]+ calcd. for
C10H15N 149.1199, found 149.1203.
1,7-Diphenyl-4-azatricyclo[3.3.1.02,7]non-3-ene 13b
Synthesis according to GP2 from dihydropyridine 11b (700 mg,
1.63 mmol) and TFA (2.81 g, 24.4 mmol, 1.89 mL) in pentane
(16 mL). Purification by FC (Al2O3-basic, activity III, pentane/CH2Cl2/
MeOH 87:10:3) afforded imine 13b.
Colorless solid (417 mg, 94 %); Rf = 0.34 (Al2O3; pentane/CH2Cl2/
MeOH 87:10:3); m.p. 95 °C; 1H NMR (500 MHz, CDCl3): δ = 8.57 (d,
J = 3.7 Hz, 1 H, NCHCH), 7.33–7.26 (m, 4 H, CCCHCHCH), 7.21–7.15
(m, 2 H, CCCHCHCH), 7.08–7.01 (m, 4 H, CCCHCHCH), 4.76–4.69 (m,
1 H, NCH(CH2)2), 3.34 (d, J = 3.6 Hz, 1 H, NCHCH), 2.78 (dt, J = 9.0/
2.2 Hz, 1 H, CCH2bC), 2.15–2.06 (m, 3 H, 2 × NCHCH2b, CCH2aC), 1.35
(d, J = 13.5 Hz, 2 H, 2 × NCHCH2a); 13C NMR (125 MHz, CDCl3): δ =
166.7 (NCHCH), 147.1 (CCCH2), 128.6 (CCHCHCH), 126.3 (CCHCHCH),
125.1 (CCHCHCH), 56.6 (NCH(CH2)2), 48.9 (NCHCH), 45.6 (CCH2C), 42.4
(CH2C), 40.2 (NCH(CH2)2); IR (KBr): ν̃ = 3051, 3020, 2960, 2926, 2846,
1610, 1599, 1495, 1444, 1340, 1205, 1070, 752, 700, 540, 482 cm–1;
HRMS (EI): m/z [M]+ calcd. for C20H19N 273.1512, found 273.1514.
3,6-Dimethyl-9-azatricyclo[4.3.1.03,7]dec-8-ene 13c
Synthesis according to GP2 from dihydropyridine 11c (2.32 g,
7.26 mmol) and TFA (20.7 g, 109 mmol, 13.9 mL) in pentane (72 mL).
Purification by FC (Al2O3-basic, activity III, pentane/CH2Cl2/MeOH
88:10:2) afforded imine 13c.
Yellow oil (735 mg (62 %); Rf = 0.58 (Al2O3; pentane/CH2Cl2/MeOH
88:10:2); 1H NMR (500 MHz, CDCl3): δ = 8.20 (d, J = 4.1 Hz, 1 H,
NCHCH), 4.14 (p, J = 2.6 Hz, 1 H, NCH(CH2)2), 2.11 (d, J = 4.1 Hz,
1 H, NCHCH), 1.67–1.60 (m, 2 H, 2 × CCH2bCH2), 1.57–1.50 (m, 2 H,
2 × CCH2aCH2), 1.43–1.37 (m, 2 H, 2 × NCHCH2b), 1.21–1.15 (m, 2 H,
2 × NCHCH2a), 0.94 (s, 6 H, 2 × CH3); 13C NMR (125 MHz, CDCl3): δ =
171.2 (NCHCH), 56.9 (NCHCH), 55.2 (NCH(CH2)2), 42.7 (NCH(CH2)2),
42.2 (CH2C), 39.8 (CH2CH2), 28.7 (CH3); IR (film): ν̃ = 2997, 2947, 2866,
2360, 1616, 1454, 1375, 1340, 1304, 1172, 1097, 997 cm–1; HRMS
(EI): m/z [M]+ calcd. for C11H17N 163.1356, found 163.1365.
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3,6-Diphenyl-9-azatricyclo[4.3.1.03,7]dec-8-ene 13d
Synthesis according to GP2 from dihydropyridine 11d (3.11 g,
7.00 mmol) and TFA (12.0 g, 105 mmol, 8.0 mL) in pentane (70 mL).
Purification by FC (Al2O3-basic, activity III, pentane/CH2Cl2/MeOH
88.5:10:1.5) afforded imine 13d.
Beige solid (1.92 g, 95 %); Rf = 0.42 (Al2O3; pentane/CH2Cl2/MeOH
88.5:10:1.5); m.p. 140 °C; 1H NMR (400 MHz, CD2Cl2): δ = 8.62 (d, J =
3.8 Hz, 1 H, NCHCH), 7.36–7.25 (m, 8 H, CCHCHCH, CCHCHCH), 7.22–
7.16 (m, 2 H, CCHCHCH), 4.30 (p, J = 2.7 Hz, 1 H, NCH(CH2)2), 3.50
(d, J = 3.8 Hz, 1 H, NCHCH), 2.25–2.12 (m, 4 H, CH2CH2), 2.08–2.00
(m, 2 H, 2 × NCHCH2b), 1.80–1.72 (m, 2 H, 2 × NCHCH2a);
13C NMR (100 MHz, CD2Cl2): δ = 169.9 (NCHCH), 150.6 (CCCH2), 129.0
(CCHCHCH), 126.3 (CCHCHCH), 126.2 (CCHCHCH), 55.4 (NCH(CH2)2),
50.7 (CH2C), 50.1 (NCHCH), 45.2 (NCH(CH2)2), 40.9 (CH2CH2); IR (KBr):
ν̃ = 3080, 3053, 2999, 2943, 2929, 2864, 1618, 1601, 1579, 1493,
1446, 1338, 1302, 1080, 906, 764, 712, 700, 546 cm–1; HRMS (EI):
m/z [M]+ calcd. for C21H21N 287.1669, found 287.1676.
3,7-Dimethyl-10-azatricyclo[5.3.1.03,8]undec-9-ene 13e
Synthesis according to GP2 from dihydropyridine 11e (850 mg,
2.55 mmol) and TFA (4.40 g, 38.2 mmol, 2.95 mL) in pentane
(26 mL). Purification by FC (Al2O3-basic, activity III, pentane/CH2Cl2/
MeOH 88:10:2) afforded imine 13e.
Yellow oil (353 mg, 78 %); Rf = 0.30 (Al2O3; pentane/CH2Cl2/MeOH
88:10:2); 1H NMR (400 MHz, CDCl3): δ = 8.38 (d, J = 4.2 Hz, 1 H,
NCHCH), 4.22–4.16 (m, 1 H, NCH(CH2)2), 1.74 (d, J = 4.2 Hz, 1 H,
NCHCH), 1.54–1.44 (m, 2 H, CH2CH2CH2), 1.40–1.30 (m, 4 H,
2 × NCHCH2b, 2 × CCH2bCH2), 1.12–1.00 (m, 4 H, 2 × NCHCH2a,
2 × CCH2aCH2), 0.81 (s, 6 H, 2 × CH3); 13C NMR (100 MHz, CDCl3): δ =
175.5 (NCHCH), 55.9 (NCH(CH2)2), 53.1 (NCHCH), 37.7 (CH2CH2CH2),
35.7 (NCH(CH2)2), 32.9 (CH2C), 32.1 (CH3), 19.1 (CH2CH2CH2); IR (film):
ν̃ = 3049, 2997, 2924, 2864, 2843, 1614, 1456, 1375, 1336, 1309,
1178, 1076, 1014, 984, 895, 708 cm–1; HRMS (ESI): m/z [M + H]+
calcd. for C12H20N 178.1590, found 178.1590.
3,7-Diphenyl-10-azatricyclo[5.3.1.03,8]undec-9-ene 13f
Synthesis according to GP2 from dihydropyridine 11f (600 mg,
1.31 mmol) and TFA (2.26 g, 19.7 mmol, 1.5 mL) in pentane (13 mL).
Purification by FC (Al2O3-basic, activity III, pentane/CH2Cl2/MeOH
88:10:2) afforded imine 13f.
Colorless solid (293 mg, 74 %); Rf = 0.20 (Al2O3; pentane/CH2Cl2/
MeOH 88:10:2); m.p. 193 °C; 1H NMR (400 MHz, CDCl3): δ = 8.40 (d,
J = 3.7 Hz, 1 H, NCHCH), 7.40–7.34 (m, 4 H, CCHCHCH), 7.34–7.27
(m, 4 H, CCHCHCH), 7.16 (tt, J = 7.2/1.4 Hz, 2 H, CCHCHCH), 4.41–
4.33 (m, 1 H, NCH(CH2)2), 3.47 (d, J = 3.7 Hz, 1 H, NCHCH), 2.11–1.98
(m, 4 H, NCH(CH2)2), 1.90 (qt, J = 13.6/3.7 Hz, 1 H, CH2CH2bCH2),
1.84–1.69 (m, 3 H, 2 × CCH2bCH2, CH2CH2aCH2), 1.49 (dt, J = 13.3/
4.0 Hz, 2 H, 2 × CCH2aCH2); 13C NMR (100 MHz, CDCl3): δ = 173.8
(NCHCH), 151.8 (CCCH2), 128.5 (CCHCHCH), 126.3 (CCHCHCH), 125.9
(CCHCHCH), 54.6 (NCH(CH2)2), 45.1 (NCHCH), 41.4 (CCH2), 40.1
(CH2CH2CH2), 36.8 (NCH(CH2)2), 19.9 (CH2CH2CH2); IR (KBr): ν̃ = 3055,
3022, 2939, 2918, 2846, 1610, 1495, 1442, 1354, 1286, 1082, 1026,
901, 756, 702, 548 cm–1; HRMS (ESI): m/z [M + H]+ calcd. for C22H24N
302.1903, found 302.1902.
3,5-Dimethyl-7(1,5)imidazolatricyclo[3.2.1.03,6]octaphan 14a
Synthesis according to GP3 from imine 13a (37 mg, 0.25 mmol),
TosMIC (72 mg, 0.37 mmol), N-(tosylmethyl)formamide (157 mg,
0.736 mmol) and tBuNH2 (109 mg, 1.47 mmol, 0.16 mL) in methanol
(2.5 mL). Purification by FC (SiO2, EtOAc/MeOH/NEt3 93:5:2) afforded
imidazole 14a.
Colorless oil (29 mg, 63 %); Rf = 0.23 (SiO2, EtOAc/MeOH/NEt3




European Journal of Organic Chemistry
1 H, CCHN), 4.62 (br s, 1 H, NCH(CH2)2), 2.75 (s, 1 H, CCHC), 1.90 (dd,
J = 12.8/2.7 Hz, 2 H, NCH(CH2b)2), 1.74 (dt, J = 9.3/2.1 Hz, 1 H,
CCH2bC), 1.46 (d, J = 9.3 Hz, 1 H, CCH2aC), 1.29–1.21 (m, 2 H,
NCH(CH2a)2), 0.97 (s, 6 H, 2 × CH3); 13C NMR (125 MHz, CDCl3): δ =
130.6 (NCHN), 129.9 (CCHN), 122.6 (CCHN), 50.7 (NCH(CH2)2), 49.1
(CCH2C), 45.1 (CCHC), 41.9 (NCH(CH2)2), 40.0 (CCH3), 25.3 (CH3);
IR (film): ν̃ = 3374, 2944, 2860, 1671, 1479, 1455, 1397, 1374, 1333,
1275, 1234, 1193, 1109, 1091, 953, 936, 799, 658 cm–1; HRMS (ESI):
m/z [M + H]+ calcd. for C12H17N2 189.1386, found 189.1385.
3,5-Diphenyl-7(1,5)imidazolatricyclo[3.2.1.03,6]octaphan 14b
Synthesis according to GP3 from imine 13b (200 mg, 0.732 mmol),
TosMIC (214 mg, 1.10 mmol), N-(tosylmethyl)formamide (468 mg,
2.19 mmol) and tBuNH2 (324 mg, 4.39 mmol, 0.46 mL) in methanol
(7.5 mL). Purification by FC (SiO2, EtOAc/MeOH/NEt3 93:5:2) afforded
imidazole 14b.
Colorless solid (134 mg, 59 %); Rf = 0.31 (SiO2, EtOAc/MeOH/NEt3
93:5:2); m.p. 162 °C; 1H NMR (400 MHz, CD2Cl2): δ = 7.63 (s, 1 H,
NCHN), 7.29–7.22 (m, 4 H, CCHCH), 7.16 (tt, J = 7.4/1.3 Hz, 2 H,
CCHCHCH), 7.11–7.05 (m, 4 H, CCHCH), 7.00 (s, 1 H, CCHN), 4.90 (br
s, 1 H, NCH(CH2)2), 3.74 (s, 1 H, CCHC), 2.76 (dt, J = 9.2/2.2 Hz, 1 H,
CCH2bC), 2.41 (dd, J = 13.2/3.2 Hz, 2 H, NCH(CH2b)2), 2.28 (d, J =
9.2 Hz, 1 H, CCH2aC), 1.81–1.73 (m, 2 H, NCH(CH2a)2); 13C
NMR (125 MHz, CD2Cl2): δ = 147.8 (CCHCH), 131.7 (NCHN), 130.5
(CCHN), 128.9 (CCHCH), 126.8 (CCHCHCH), 125.5 (CCHCH), 122.5
(CCHN), 51.3 (NCH(CH2)2), 46.6 (CCH2), 45.5 (CCH2C), 45.1 (CCHC),
44.6 (NCH(CH2)2); IR (KBr): ν̃ = 3103, 3024, 2937, 1676, 1603, 1493,
1479, 1444, 1398, 1327, 1288, 1230, 1209, 1092, 943, 756, 698, 660,
528 cm–1; HRMS (ESI): m/z [M + H]+ calcd. for C22H21N2 313.1699,
found 313.1697.
3,6-Dimethyl-8(1,5)imidazolatricyclo[4.2.1.03,7]nonaphan 14c
Synthesis according to GP3 from imine 13c (200 mg, 1.23 mmol),
TosMIC (359 mg, 1.84 mmol), N-(tosylmethyl)formamide (784 mg,
3.68 mmol) and tBuNH2 (543 mg, 7.35 mmol, 0.78 mL) in methanol
(12.5 mL). Purification by FC (SiO2, EtOAc/MeOH/NEt3 93:5:2) af-
forded imidazole 14c
Colorless solid (226 mg, 91 %); Rf = 0.28 (SiO2, EtOAc/MeOH/NEt3
93:5:2); m.p. 99 °C; 1H NMR (400 MHz, CDCl3): δ = 7.44 (s, 1 H,
NCHN), 6.89 (s, 1 H, CCHN), 4.35 (p, J = 2.7 Hz, 1 H, NCH(CH2)2), 2.37
(s, 1 H, CCHC), 1.74–1.63 (m, 6 H, NCH(CH2b)2, CCH2CH2C), 1.46–1.38
(m, 2 H, NCH(CH2a)2), 0.88 (s, 6 H, 2 × CH3); 13C NMR (100 MHz,
CDCl3): δ = 130.3 (NCHN), 129.9 (CCHN), 124.4 (CCHN), 51.6 (CCHC),
49.4 (NCH(CH2)2), 46.1 (NCH(CH2)2), 43.6 (CCH3), 39.5 (CCH2CH2C),
27.3 (CH3); IR (KBr): ν̃ = 3086, 2950, 2922, 2867, 1693, 1484, 1469,
1448, 1394, 1236, 1203, 1085, 942, 850, 803, 661 cm–1; HRMS (ESI):
m/z [M + H]+ calcd. for C13H19N2 203.1543, found 203.1541.
3,6-Diphenyl-8(1,5)imidazolatricyclo[4.2.1.03,7]nonaphan 14d
Synthesis according to GP3 from imine 13d (600 mg, 2.09 mmol),
TosMIC (611 mg, 3.13 mmol), N-(tosylmethyl)formamide (1.34 g,
6.26 mmol) and tBuNH2 (925 mg, 12.5 mmol, 1.32 mL) in methanol
(21 mL). Purification by FC (SiO2, EtOAc/MeOH/NEt3 93:5:2) afforded
imidazole 14d.
Colorless solid (380 mg, 56 %); Rf = 0.32 (SiO2, EtOAc/MeOH/NEt3
93:5:2); m.p. 160 °C; 1H NMR (400 MHz, CD2Cl2): δ = 7.42 (s, 1 H,
NCHN), 7.30–7.20 (m, 8 H, CCHCH, CCHCH), 7.18–7.10 (m, 2 H,
CCHCHCH), 6.95 (t, J = 0.6 Hz, 1 H, CCHN), 4.62 (p, J = 2.7 Hz, 1 H,
NCH(CH2)2), 3.94 (s, 1 H, CCHC), 2.39–2.32 (m, 2 H, NCH(CH2b)2),
2.30–2.21 (m, 4 H, CCH2CH2C), 2.17–2.10 (m, 2 H, NCH(CH2a)2);
13C NMR (100 MHz, CD2Cl2): δ = 149.4 (CCHCH), 130.9 (NCHN), 130.4
(CCHN), 128.9 (CCHCH), 126.4 (CCHCHCH), 126.1 (CCHCH), 124.6
(CCHN), 50.8 (CCH2), 49.9 (NCH(CH2)2), 48.3 (NCH(CH2)2), 45.9
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(CCHC), 40.8 (CCH2CH2C); IR (KBr): ν̃ = 3020, 2947, 2868, 1682, 1599,
1495, 1481, 1466, 1444, 1396, 1342, 1273, 1228, 1092, 1026, 945,
760, 729, 700, 656, 540 cm–1; HRMS (ESI): m/z [M + H]+ calcd. for
C23H23N2 327.1856, found 327.1854.
3,7-Dimethyl-9(1,5-2H2)imidazolatricyclo[5.2.1.03,8]decaphan 14e
Synthesis according to GP3 from imine 13e (22 mg, 0.12 mmol),
TosMIC (36 mg, 0.18 mmol), N-(tosylmethyl)formamide (78 mg,
0.37 mmol) and tBuNH2 (54 mg, 0.73 mmol, 78 μL) in (2H4)CH3OH
(1.25 mL). Purification by FC (SiO2, EtOAc/MeOH/NEt3 93:5:2) af-
forded imidazole 14e.
Colorless oil (NMR-Yield 4 mg, 14 %); Rf = 0.18 (SiO2, EtOAc/MeOH/
NEt3 93:5:2); 1H NMR (500 MHz, CD3OD): δ = 4.62–4.57 (m, 1 H,
NCH(CH2)2) 2.19 (s, 1 H, CCHC), 1.79–1.55 (m, 6 H, 3 × CH2), 1.32–
1.21 (m, 4 H, 2 × CH2), 0.69 (s, 6 H, 2 × CH3); HRMS (ESI): m/z [M +
H]+ calcd. for C14H19D2N2 219.1825, found 219.1824.
3,7-Diphenyl-9(1,5-2H2)imidazolatricyclo[5.2.1.03,8]decaphan 14f
Synthesis according to GP3 from imine 13f (18 mg, 61 μmol), Tos-
MIC (18 mg, 92 μmol), N-(tosylmethyl)formamide (39 mg,
0.18 mmol) and tBuNH2 (27 mg, 0.37 mmol, 39 μL) in (2H4)CH3OH
(0.63 mL). Purification by FC (SiO2, EtOAc/MeOH/NEt3 93:5:2) af-
forded imidazole 14f.
Colorless oil (NMR-Yield 2 mg, 12 %); Rf = 0.18 (SiO2, EtOAc/MeOH/
NEt3 93:5:2); 1H NMR (400 MHz, CD3OD): δ = 7.31–7.25 (m, 4 H,
CCHCHCH), 7.24–7.17 (m, 4 H, CCHCHCH), 7.07 (tt, J = 7.3/1.3 Hz,
2 H, CCHCHCH), 4.88–4.85 (m, 1 H, NCH(CH2)2), 3.88 (s, 1 H, CCHC),
2.47–2.37 (m, 2 H, CH2), 2.35–2.27 (m, 2 H, CH2), 2.16–2.02 (m, 1 H,
CH2b), 1.93–1.86 (m, 2 H, CH2), 1.86–1.78 (m, 1 H, CH2a), 1.77–1.66
(m, 2 H, CH2); HRMS (ESI): m/z [M + H]+ calcd. for C24H23D2N2
343.2138, found 343.2138.
5,6,7,8-Tetrahydro(1,3-2H2)imidazo[1,5-a]pyridine 14g
Synthesis according to GP3 from imine 13g (20 mg, 0.25 mmol),
TosMIC (72 mg, 0.37 mmol), N-(tosylmethyl)formamide (157 mg,
0.736 mmol) and tBuNH2 (109 mg, 1.47 mmol, 0.16 mL) in
(2H4)CH3OH (2.5 mL) at 25 °C. Purification by FC (SiO2, EtOAc/MeOH/
NEt3 93:5:2) afforded imidazole 14g.
Yellow oil (NMR-Yield 6 mg, 21 %); Rf = 0.24 (SiO2, EtOAc/MeOH/
NEt3 93:5:2); 1H NMR (500 MHz, CDCl3): δ = 3.96 (t, J = 6.1 Hz, 2 H,
NCH2), 2.75 (t, J = 6.4 Hz, 2 H, CCH2), 1.96–1.89 (m, 2 H, CH2), 1.84–
1.77 (m, 2 H, CH2); Due to rapid proton deuterium exchange of
the starting imine 13g in course of the imine enamine equilibrium
unplanned deuterium incorporation into the tetrahydropyridine
core occurred and led to a decreased signal intensity at 2.75 ppm.
HRMS (ESI): m/z [M + H]+ calcd. for C7H9D2N2 125.1042, found
125.1043.
5,6-Dihydro(1,3-2H2)imidazo[5,1-a]isoquinoline 14h
Synthesis according to GP3 from imine 13h (32 mg, 0.25 mmol),
TosMIC (72 mg, 0.37 mmol), N-(tosylmethyl)formamide (157 mg,
0.736 mmol) and tBuNH2 (109 mg, 1.47 mmol, 0.16 mL) in
(2H4)CH3OH (2.5 mL) at 25 °C. Purification by FC (SiO2, EtOAc/MeOH/
NEt3 93:5:2) afforded imidazole 14h.
Yellow oil (36 mg, 86 %); Rf = 0.21 (SiO2, EtOAc/MeOH/NEt3 93:5:2);
1H NMR (400 MHz, CD3OD): δ = 7.59–7.54 (m, 1 H, NCCCH), 7.29–
7.22 (m, 2 H, CH2CCH, NCCCHCH), 7.22–7.16 (m, 1 H, CH2CCHCH),
4.19 (t, J = 6.6 Hz, 2 H, NCH2), 3.06 (t, J = 6.6 Hz, 2 H, CCH2);
13C NMR (100 MHz, CD3OD): δ = 137.2 (t, NCDN), 132.7 (CH2C), 130.5
(NCC), 129.4 (NCCCHCH), 128.4 (CH2CCH, CH2CCHCH), 127.9 (NCC),
124.2 (NCCCH), 123.2 (t, NCDC), 43.0 (NCH2), 29.9 (CCH2); IR (KBr):
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1322, 1212, 1025, 947, 816, 766, 737, 717 cm–1; HRMS (ESI): m/z [M
+ H]+ calcd. for C11H9D2N2 173.1042, found 173.1042.
Dimer 18
Imine 13c (30 mg, 0.18 mmol), N-(tosylmethyl)formamide (118 mg,
0.55 mmol) and Cs2CO3 (180 mg, 0.553 mmol) were dissolved in
(2H4)CH3OH (1.88 mL) and stirred for 20 min at 25 °C. Subsequent
1H NMR analysis indicated the formation of dimer 18 to an extent
of 65 % (determined by NMR ratio relative to the methyl group of
Tos–). Purification by twofold preparative TLC (SiO2, CH2Cl2/MeOH
9:1) afforded dimer 18 (admixed with a substance (ratio 80:20) that
is most likely a diastereomer of dimer 18).
Colorless crystals (1.8 mg, 4 %); Rf = 0.70 (SiO2, CH2Cl2/MeOH 9:1);
m.p. 156 °C; 1H NMR (500 MHz, CD3OD): δ = 8.13 (s, 2 H, NCHO),
4.53 (d, J = 13.1 Hz, 2 H, 2 × NCH2bN), 4.31 (d, J = 2.9 Hz, 2 H,
2 × NCHCH), 3.99 (d, J = 13.1 Hz, 2 H, 2 × NCH2aN), 2.87 (p, J =
2.8 Hz, 2 H, 2 × NCHCH2), 1.81 (dt, J = 12.7/2.8 Hz, 2 H,
2 × NCHCH2d), 1.74 (dt, J = 13.5/2.9 Hz, 2 H, 2 × NCHCH2c), 1.58–
1.37 (m, 12 H, 2 × NCHCH2b, 4 × CH3CCH2, 2 × NCHCH), 1.28–1.19
(m, 8 H, 2 × CH3, 2 × NCHCH2a), 1.09 (s, 6 H, 2 × CH3);
13C NMR (125 MHz, CD3OD): δ = 164.3 (2 × NCHO), 92.8
(2 × NCHCH), 56.6 (2 × NCH2N), 51.5 (2 × NCHCH2), 50.8
(2 × NCHCH), 47.9 (2 × NCHCH2), 42.4 (2 × CH3CCH2), 41.4
(2 × CH3CCH2), 41.3 (2 × CCH3), 41.2 (2 × NCHCH2), 39.8 (2 × CCH3),
29.1 (2 × CH3), 26.7 (2 × CH3); IR (KBr): ν̃ = 2941, 2924, 2866, 1657,
1365, 1313, 1261, 1238, 1174, 1146, 1120, 986, 970, 733 cm–1; HRMS
(ESI): m/z [M + H]+ calcd. for C26H41O2N4 441.3224, found 441.3222.
Keywords: Cyclic Imine · Cycloaddition · Nitrogen
heterocycles · Organocatalysis · TosMIC
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